Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Main|Search|PHGKB
Search PHGKB:

Last Posted: Sep 12, 2023
spot light Highlights

Epigenetics of Early-Life Socioeconomic Stressors and the Impact on Childhood Body Mass Index—Potential Mechanism and Biomarker?
UP Gujral et al, JAMA Pediatrics, September 5, 2023

From the paper: "a recent study indicates that salivary epigenetics, an easy measure to obtain in field or clinic, can be used to further explore the questions of pediatric obesity and related outcomes. Epigenetic and physiological BMI may be present at birth and remain stable throughout childhood and adolescence. These findings also add further evidence to a critical window, that of early life, at which to intervene to prevent childhood and adolescent obesity."

CKD Risk Factors
CDC, June 2023 Brand

Diabetes and high blood pressure are the more common causes of CKD in most adults. Other risk factors include heart disease, obesity, a family history of CKD, inherited kidney disorders, past damage to the kidneys, and older age.

Antagonizing the Leptin Receptor in Obesity.
Clifford J Rosen et al. N Engl J Med 2023 6 (24) 2291-2293

Childhood obesity is a challenging clinical condition. Secondary causes of obesity are often sought but rarely found, and few can be addressed by successful therapeutic interventions. Leptin was once hailed as a treatment for most cases of childhood obesity but quickly lost favor when resistance to leptin was noted.

Beyond genetic screening-functionality-based precision medicine in monogenic obesity.
Antje Körner et al. The lancet. Diabetes & endocrinology 2023 2 (3) 143-144

Most genes causing monogenic obesity are implicated in the central energy regulatory circuits of the leptin-melanocortin pathway. Even though monogenic obesity is still a rare disease entity, identifying these patients is important since there are now promising treatment options such as setmelanotide, a melanocortin receptor agonist, which was recently approved by the US Food and Drug Administration and European Medicines Agency

Search Result Summary


Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP